OncoCyte Co. (NASDAQ:OCX) CFO Andrea S. James Buys 97,561 Shares of Stock

OncoCyte Co. (NASDAQ:OCX) CFO Andrea S. James purchased 97,561 shares of the company’s stock in a transaction on Friday, February 7th. The shares were purchased at an average cost of $2.05 per share, for a total transaction of $200,000.05. Following the completion of the transaction, the chief financial officer now directly owns 151,231 shares of the company’s stock, valued at approximately $310,023.55. This represents a 181.78 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

OncoCyte Trading Up 14.5 %

NASDAQ:OCX opened at $2.37 on Wednesday. OncoCyte Co. has a one year low of $1.92 and a one year high of $3.48. The firm’s fifty day moving average price is $2.20 and its two-hundred day moving average price is $2.71.

OncoCyte (NASDAQ:OCX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.54). OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. The company had revenue of $0.12 million during the quarter. During the same quarter in the prior year, the company posted ($0.57) EPS. On average, sell-side analysts forecast that OncoCyte Co. will post -2.57 EPS for the current fiscal year.

Hedge Funds Weigh In On OncoCyte

An institutional investor recently raised its position in OncoCyte stock. FNY Investment Advisers LLC raised its stake in OncoCyte Co. (NASDAQ:OCX) by 15.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 49,377 shares of the company’s stock after purchasing an additional 6,481 shares during the period. FNY Investment Advisers LLC owned 0.29% of OncoCyte worth $117,000 at the end of the most recent quarter. Institutional investors and hedge funds own 55.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. StockNews.com assumed coverage on shares of OncoCyte in a research report on Monday, January 13th. They set a “sell” rating on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $4.25 price target on shares of OncoCyte in a research report on Wednesday, November 13th.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.